Sqz Biotechnologies Company · OTC:SQZB
Sqz Biotechnologies — Investor Presentation (September 2021)
29 slides from Sqz Biotechnologies's investor presentation, Sep 13, 2021
Slide 1: Empower Cells to Change Lives
Exhibit 99.2 Empower Cells to Change Lives® September 2021
Slide 2: Forward Looking Statements and Legal Disclaimers
Forward Looking Statements and Legal Disclaimers This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forwa
Slide 3: SQZ Biotech: Unlocking the Full Potential of Cell Therapies
SQZ Biotech: Unlocking the Full Potential of Cell Therapies üSQZ Technology addresses fundamental challenge of engineering diverse cell functions • Multiple cell therapy platforms with expansive potential across oncology, autoimmune and infectious diseases • Partnership with Roche and potential for
Slide 4: Unique Cell Squeeze Technology Enables Differentiated Capabilities
® Unique Cell Squeeze Technology Enables Differentiated Capabilities Cells and target cargo Cell membranes are Membranes 1 3 5 together in suspension temporarily disrupted reseal Cells are squeezed through SQZ Target cargo enters the 2 4 chip at high speeds cytosol of the cells Applicable to diverse
Slide 5: Manufacturing: Fast, Reliable and Potential to Expand Cell Therapy Access
Manufacturing: Fast, Reliable and Potential to Expand Cell Therapy Access Manufacturing Process and Patient Experience Approach Strengths and Considerations ~24‐113 days vein‐to‐vein • High cost • Lymphodepletion Autologous • Bridging chemotherapy• Long turn‐around times ~10‐12 days enrollment to in
Slide 6: Addressing Challenges That Could Unlock Broader Cell Therapy Universe
Addressing Challenges That Could Unlock Broader Cell Therapy Universe Universe of Possible Cell Therapies Hematology Oncology Viral Cell Squeeze Solid Tumors Electroporation Transduction Technology Ability to retain cell ++ +++ health and function Flexibility in cell Autoimmune ++ + +++ types and ca
Slide 7: Directing Immune System to Drive Antigen Specific Activation and Tolerization
Directing Immune System to Drive Antigen Specific Activation and Tolerization 1. Antigen (What to target) 2. Context (Activation vs. Tolerance) Determinants Antigen presenting cells (APCs) Once a T cell’s TCR is engaged, it looks for show peptide antigen on MHC‐I clues via APC surface receptors and
Slide 8: Strategy: Leverage Flexible Technology To Quickly Expand Indications From Each Platform
Strategy: Leverage Flexible Technology To Quickly Expand Indications From Each Platform Autoimmune Disease Chronic Infectious Disease Oncology Annual incidence (‘000s) Prevalence (M) Prevalence (M) 3 3 400 KRAS 300 2 2 Potential Patient 200 Impact: HPV 1 1 (Patient numbers, US) 100 0 0 0 HBV HIV Oth
Slide 9: Diverse Pipeline: Synergistic in Execution yet Independent in Mechanism
Diverse Pipeline: Synergistic in Execution yet Independent in Mechanism CELL SOURCE/ PLATFORM INDICATION PRE‐CLINICAL PHASE 1/2 CARGO H&N, Cervical, Anal PBMC + Peptide Other Solid Tumors SQZ APCs RBC H&N, Cervical, Anal + Peptide KRAS mut Solid Tumors + SQZ AACs Adjuvant Other Solid Tumors PBMC + S
Slide 10: Oncology SQZ Approach
Oncology SQZ™ Approach SQZ eAPCs SQZ APCs SQZ AACs 10
Slide 11: Importance of Engineering Antigen Presentation for Powerful CD8 Activation
Importance of Engineering Antigen Presentation for Powerful CD8 Activation Strong Correlation of CD8 TILs with Clinical Response CD8 T Cell Infiltration as a Prognostic Indicator in Solid Tumors PC Tumeh et. al. Nature. 2014 Responders Progressors Balermpas, et. Al. British Journal of Cancer. Octobe
Slide 12: Oncology SQZ Approach
Oncology SQZ™ Approach SQZ AACs SQZ APCs SQZ eAPCs 12
Slide 13: Overcoming the Challenge of Cancer Vaccines
Overcoming the Challenge of Cancer Vaccines TM Typical Cancer Vaccine Mechanism: SQZ APC Mechanism: Cross‐Presentation Direct Presentation MHC‐I = CD8 T Cell MHC‐I = CD8 Activation Endocytosis Squeezed Antigen MHC‐II = CD4 + antibodies • Primarily generates MHC‐II presentation for CD4 and • Primaril
Slide 14: Ongoing Phase 1/2 Trial: Flexible Design, Combination Data in 2022
Ongoing Phase 1/2 Trial: Flexible Design, Combination Data in 2022 Monotherapy Enrollment Complete Open for Enrollment 0.5M cells 2.5M cells 2.5M cells 5M cells per kg per kg per kg (DP) per kg (DP) Cohort 1 Cohort 2 Cohort 3 Cohort 3a Combination Therapy Atezo Ipi/Nivo Other I/O SQZ‐APC‐HPV Combo C
Slide 15: Phase 1 Mono Data: SQZ APCs Demonstrated Safety and Reliable Manufacturing
* Ph 1 Mono Data: SQZ™ APCs Demonstrated Safety and Reliable Manufacturing Safety • No patient met pre‐specified DLT criteria Total • No related Grade ≥3 SAEs reported: Patient Demographics (N=12) Age, years • Grade 2 (related) – CRS (1 pt) Median (Min, Max) 62.5 (47, 68) • Unrelated SAEs ‐ Grade 3
Slide 16: Encouraging Increase in Immune Activity in Certain Patients
* Encouraging Increase in Immune Activity in Certain Patients Case Study: Patient 2 (Cohort 1 ‐ 0.5e6/kg q3w) SD SD BOR 345+ 246+ Survival FU* Dose • 65‐year‐old woman – cervical cancer RMH 10 • 3.5 years after diagnosis following treatment with (1) cisplatin/paclitaxel/ bevacizumab [BOR=CR] and (2)
Slide 17: Next Step: Combinations - Potential Synergies with Other I/O Compounds
Next Step: Combinations ‐ Potential Synergies with Other I/O Compounds Antigen‐Specific Responses could be Preclinical data demonstrated synergistic potential of SQZ APCs in combination with Roche PD1‐IL2v Amplified with Combination TM SQZ APCs drive I/O drugs tumor‐specific T enhance activity cell
Slide 18: Oncology SQZ Approach
Oncology SQZ™ Approach SQZ eAPCs SQZ AACs SQZ APCs 18
Slide 19: 2nd Generation APCs: Enhancing with Combination-like Functionality
nd 2 Generation APCs: Enhancing with Combination‐like Functionality TM SQZ eAPC Enhanced APCs (eAPC): • Multiple mRNA as cargo SQZ eAPC • Broader antigen repertoire in mRNA potentially Signals 2 3 increases addressable population 2‐3x 1 • Addition of co‐stimulatory factors and cytokines: MHC‐I membr
Slide 20: Oncology SQZ Approach
Oncology SQZ™ Approach SQZ APCs SQZ AACs SQZ eAPCs 20
Slide 21: Creating Antigen Carriers from RBCs to Direct Immune Response
Creating Antigen Carriers from RBCs to Direct Immune Response Antigen Lymphoid Organ Presentation Cargo SQZ™ Antigen Carriers • Antigen Carriers generated by squeezing RBCs deliver antigen to guide a specific immune response • Leverage the natural process by which RBCs are regularly cleared by the b
Slide 22: SQZ AACs Demonstrated Robust Activation in Preclinical Studies
SQZ™ AACs Demonstrated Robust Activation in Preclinical Studies Lymphoid Organ Activation Antigen + Activating Adjuvant T cell activation SQZ™ AACs 1. High Quantities of CD8+ T Cells 3. High Quality T Cell Responses 2. Specific T Cell Responses As presented at SITC 2020 22 Data in HPV Tumor Model
Slide 23: Flexible AAC Candidate Trial Design | Monotherapy & Combination with ICIs
Flexible AAC Candidate Trial Design | Monotherapy & Combination with ICIs Monotherapy 2022 IND 50 M Dose determined by Additional KRAS‐Mutant AACs/kg Cohort 1 observations Cohorts Tumors Cohort 1 Cohort 2 Combination Therapy SQZ‐AAC‐HPV Multiple I/O Phase 1/2 Trial Information Combo Cohorts • Basket
Slide 24: Autoimmune Diseases SQZ Approach
Autoimmune Diseases SQZ™ Approach SQZ TACs 24
Slide 25: SQZ TACs - Directing Tolerogenic Immune Response
SQZ™ TACs ‐ Directing Tolerogenic Immune Response SQZ™ Tolerizing Antigen Carriers (SQZ TACs) Leveraging antigen carriers from RBCs squeezed with antigen only (no adjuvant) tolerize the immune response to that antigen Activation SQZ Cargo Antigen + Activating Adjuvant Lymphoid Organ T cell activatio
Slide 26: TACs Prevented Onset of Type 1 Diabetes Through Multiple Mechanisms
TACs Prevented Onset of Type 1 Diabetes Through Multiple Mechanisms SQZ™ TACs Demonstrate Durable Disease TACs Restore Tolerance Through Multiple Pathways Altering Benefit in T1D Preclinical Models Central to Complex Autoimmune Diseases 1. Decrease Autoreactive T Cells 3. Induce Bystander Suppressio
Slide 27: SQZ TAC Opportunity in Celiac Disease
SQZ™ TAC Opportunity in Celiac Disease Celiac Disease: Lead SQZ TAC Indication with High Unmet Need for a Tolerizing Therapy Potential Year Diagnosed CeD, US expansion SQZ‐TAC‐CeD Target Product Profile 2020 1.06M populations Initial target Long‐acting tolerization for release population: 2025 1.55M
Slide 28: Infectious Diseases and beyond
Infectious Diseases and beyond 28
Slide 29: Potential for Multiple Clinical Readouts In 2022
Potential for Multiple Clinical Readouts In 2022 Milestones through end of 2022 Investment Highlights • Phase 1/2 Add’l Monotherapy data • Phase 1/2 Combination data SQZ APCs ü Proprietary technology with potential to expand • Phase 1/2 data application of cell therapies • KRAS IND submission SQZ AA
SQZ Biotechnologies — Investor Presentation (September 2021) on 6ix